Magnesiumstoffwechsel

Zusammenfassung

Störungen des Magnesiumstoffwechsels, insbesondere eine Hypomagnesiämie, sind häufig. Unklar ist aktuell noch, welche laborchemische Messmethode die beste ist, um den Magnesiumhaushalt zu bewerten. Am häufigsten wird das Gesamt-Mg im Serum gemessen. Multiple Assoziationsdaten deuten an, dass ein Mangel an Magnesium mit einem erhöhten kardiovaskulären Risiko und vermindertem Überleben assoziiert ist. Umgekehrt scheint eine leichte Hypermagnesiämie auch bei Patienten mit schwerer Niereninsuffizienz mit einem verbesserten Ergebnis assoziiert zu sein. Die vorliegende Übersicht fasst die aktuelle Datenlage über protektive Effekte des Magnesiums zusammen und nimmt Stellung zu der noch sehr begrenzten Datenlage bei Magnesiuminterventionsstudien.

Abstract

Disturbances in magnesium homeostasis are frequent clinical conditions, particularly the prevalence of hypomagnesaemia is high. However, it remains an open question which laboratory method is optimal to assess the magnesium level in the body. Most frequently physicians measure total magnesium in serum. Many associative data from observational studies point towards an association between low magnesium levels and increased cardiovascular risk as well as increased mortality. Vice versa, normal-to-high magnesium levels in patients with advanced renal failure translate to a better outcome. The present review summarizes our knowledge on protective effects of magnesium. Additionally, we address the limited evidence supporting targeted magnesium supplementation

Schlüsselwörter

Herzrhythmus - Kalzifikation - Mg-Mangel

Keywords

heart rhythm - calcification - magnesium deficiency

• Literatur

• 1 Maguire ME, Cowan JA. Magnesium chemistry and biochemistry. Biometals 2002; 15: 203-210
• 2 Fox C, Ramsoomair D, Carter C. Magnesium: its proven and potential clinical significance. South Med J. 2001; 94: 1195-1201
• 3 Jahnen-Dechent W, Ketteler M. Magnesium basics. Clin Kidney J 2012; 5: i3-i14
• 4 Elin RJ. Assessment of magnesium status for diagnosis and therapy. Magnes Res 2010; 23: S194-S198
• 5 Grober U, Schmidt J, Kisters K. Magnesium in Prevention and Therapy. Nutrients 2015; 7: 8199-8226
• 6 Floege J. Magnesium in CKD: more than a calcification inhibitor?. J Nephrol 2015; 28: 269-277
• 7 Kolte D, Vijayaraghavan K, Khera S et al. Role of magnesium in cardiovascular diseases. Cardiol Rev 2014; 22: 182-192
• 8 Hashizume N, Mori M. An analysis of hypermagnesemia and hypomagnesemia. Jpn J Med 1990; 29: 368-372
• 9 Van Laecke S, Van Biesen W. Hypomagnesaemia in kidney transplantation. Transplant Rev (Orlando ) 2015; 29: 154-160
• 10 Konrad M, Schlingmann KP. Inherited disorders of renal hypomagnesaemia. Nephrol Dial Transplant 2014; 29 (Suppl 4) iv63-iv71
• 11 de Baaij JH, Hoenderop JG, Bindels RJ. Magnesium in man: implications for health and disease. Physiol Rev 2015; 95: 1-46
• 12 Kafka H, Langevin L, Armstrong PW. Serum magnesium and potassium in acute myocardial infarction. Influence on ventricular arrhythmias. Arch Intern Med 1987; 147: 465-469
• 13 Ceremuzynski L, Gebalska J, Wolk R, Makowska E. Hypomagnesemia in heart failure with ventricular arrhythmias. Beneficial effects of magnesium supplementation. J Intern Med 2000; 247: 78-86
• 14 Rubeiz GJ, Thill-Baharozian M, Hardie D, Carlson RW. Association of hypomagnesemia and mortality in acutely ill medical patients. Crit Care Med 1993; 21: 203-209
• 15 Camm AJ, Kirchhof P, Lip GY et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31: 2369-2429
• 16 Miller S, Crystal E, Garfinkle M et al. Effects of magnesium on atrial fibrillation after cardiac surgery: a meta-analysis. Heart 2005; 91: 618-623
• 17 Zehender M, Meinertz T, Faber T et al. Antiarrhythmic effects of increasing the daily intake of magnesium and potassium in patients with frequent ventricular arrhythmias. Magnesium in Cardiac Arrhythmias (MAGICA) Investigators. J Am Coll Cardiol 1997; 29: 1028-1034
• 18 ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. Lancet 1995; 345: 669-685
• 19 Early administration of intravenous magnesium to high-risk patients with acute myocardial infarction in the Magnesium in Coronaries (MAGIC) Trial: a randomised controlled trial. Lancet 2002; 360: 1189-1196
• 20 Sarrafzadegan N, Khosravi-Boroujeni H, Lotfizadeh M et al. Magnesium status and the metabolic syndrome: A systematic review and meta-analysis. Nutrition 2016; 32: 409-417
• 21 Kass L, Weekes J, Carpenter L. Effect of magnesium supplementation on blood pressure: a meta-analysis. Eur J Clin Nutr 2012; 66: 411-418
• 22 Cao Y, Wang C, Guan K et al. Association of magnesium in serum and urine with carotid intima-media thickness and serum lipids in middle-aged and elderly Chinese: a community-based cross-sectional study. Eur J Nutr 2016; 55: 219-226
• 23 Hruby A, O’Donnell CJ, Jacques PF et al. Magnesium intake is inversely associated with coronary artery calcification: the Framingham Heart Study. JACC Cardiovasc Imaging 2014; 7: 59-69
• 24 Jee SH, Miller 3rd ER, Guallar E et al. The effect of magnesium supplementation on blood pressure: a meta-analysis of randomized clinical trials. Am J Hypertens 2002; 15: 691-696
• 25 Reffelmann T, Dorr M, Ittermann T et al. Low serum magnesium concentrations predict increase in left ventricular mass over 5 years independently of common cardiovascular risk factors. Atherosclerosis 2010; 213: 563-569
• 26 Qu X, Jin F, Hao Y et al. Magnesium and the risk of cardiovascular events: a meta-analysis of prospective cohort studies. PLoS One 2013; 8: e57720
• 27 Adebamowo SN, Spiegelman D, Flint AJ et al. Intakes of magnesium, potassium, and calcium and the risk of stroke among men. Int J Stroke 2015; 10: 1093-1100
• 28 Adebamowo SN, Spiegelman D, Willett WC, Rexrode KM. Association between intakes of magnesium, potassium, and calcium and risk of stroke: 2 cohorts of US women and updated meta-analyses. Am J Clin Nutr 2015; 101: 1269-1277
• 29 Pham PC, Pham PM, Pham SV et al. Hypomagnesemia in patients with type 2 diabetes. Clin J Am Soc Nephrol 2007; 2: 366-373
• 30 Dong JY, Xun P, He K, Qin LQ. Magnesium intake and risk of type 2 diabetes: meta-analysis of prospective cohort studies. Diabetes Care 2011; 34: 2116-2122
• 31 Paolisso G, Sgambato S, Pizza G et al. Improved insulin response and action by chronic magnesium administration in aged NIDDM subjects. Diabetes Care 1989; 12: 265-269
• 32 Del Gobbo LC, Song Y, Poirier P et al. Low serum magnesium concentrations are associated with a high prevalence of premature ventricular complexes in obese adults with type 2 diabetes. Cardiovasc Diabetol 2012; 11: 23
• 33 Pham PC, Pham PM, Pham PA et al. Lower serum magnesium levels are associated with more rapid decline of renal function in patients with diabetes mellitus type 2. Clin Nephrol 2005; 63: 429-436
• 34 Wyskida K, Witkowicz J, Chudek J, Wiecek A. Daily magnesium intake and hypermagnesemia in hemodialysis patients with chronic kidney disease. J Ren Nutr 2012; 22: 19-26
• 35 Alves SC, Tomasi CD, Constantino L et al. Hypomagnesemia as a risk factor for the non-recovery of the renal function in critically ill patients with acute kidney injury. Nephrol Dial Transplant 2013; 28: 910-916
• 36 Schlieper G, Schurgers L, Brandenburg V et al. Vascular calcification in chronic kidney disease: an update. Nephrol Dial Transplant 2016; 31: 31-39
• 37 Meema HE, Oreopoulos DG, Rapoport A. Serum magnesium level and arterial calcification in end-stage renal disease. Kidney Int 1987; 32: 388-394
• 38 Pasch A, Farese S, Graber S et al. Nanoparticle-based test measures overall propensity for calcification in serum. J Am Soc Nephrol 2012; 23: 1744-1752
• 39 Montes dO, Guerrero F, Martinez-Moreno JM et al. Magnesium inhibits Wnt/beta-catenin activity and reverses the osteogenic transformation of vascular smooth muscle cells. PLoS One 2014; 9: e89525
• 40 de Francisco AL, Leidig M, Covic AC et al. Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability. Nephrol Dial Transplant 2010; 25: 3707-3717
• 41 Kieboom BC, Niemeijer MN, Leening MJ et al. Serum Magnesium and the Risk of Death From Coronary Heart Disease and Sudden Cardiac Death. J Am Heart Assoc 2016; 5: e002707
• 42 Reffelmann T, Ittermann T, Dorr M et al. Low serum magnesium concentrations predict cardiovascular and all-cause mortality. Atherosclerosis 2011; 219: 280-284
• 43 Jiang L, He P, Chen J et al. Magnesium Levels in Drinking Water and Coronary Heart Disease Mortality Risk: A Meta-Analysis. Nutrients 2016; 8: 5
• 44 Fang X, Liang C, Li M et al. Dose-response relationship between dietary magnesium intake and cardiovascular mortality: A systematic review and dose-based meta-regression analysis of prospective studies. J Trace Elem Med Biol 2016;
• 45 Ishimura E, Okuno S, Yamakawa T et al. Serum magnesium concentration is a significant predictor of mortality in maintenance hemodialysis patients. Magnes Res 2007; 20: 237-244
• 46 Sakaguchi Y, Fujii N, Shoji T et al. Magnesium modifies the cardiovascular mortality risk associated with hyperphosphatemia in patients undergoing hemodialysis: a cohort study. PLoS One 2014; 9: e116273
• 47 Bundeslebensmittelschlüssel. https://blsdb.de/bls?background
• 48 https://www.dge.de/wissenschaft/referenzwerte/magnesium/